M2-型丙酮酸激酶(PKM2)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Pyruvate kinase isozymes M2 (PKM2) ,etc. by FLIA (Flow Luminescence Immunoassay)
M2PK; PKM; M2-PK; PKM1; CTHBP; OIP3; PK3; PKM; TCB; THBP1; Pyruvate kinase muscle isozyme; Thyroid hormone-binding protein 1; Cytosolic thyroid hormone-binding protein; Pyruvate Kinase, Muscle
(注:單次混測多因子不超過8個(gè)指標(biāo) )
- 編號(hào)LMA588Hu
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長3.5h
- 檢測范圍4.88-5000pg/mL
- 靈敏度最小可檢測劑量小于等于1.627 pg/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2359 ¥ 2449 ¥ 2586 ¥ 2767 ¥ 2948 ¥ 3221 ¥ 3629 計(jì)算器 ¥ 4536 添加到價(jià)格計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測M2-型丙酮酸激酶(PKM2)等多因子檢測試劑盒(流式熒光發(fā)光法),經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測,因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的M2-型丙酮酸激酶(PKM2)等多因子檢測試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測定并計(jì)算其均值,回收率為測定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 97-105 | 102 |
EDTA plasma(n=5) | 83-98 | 93 |
heparin plasma(n=5) | 97-104 | 101 |
sodium citrate plasma(n=5) | 79-95 | 87 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測定,每個(gè)樣本使用同一試劑盒重復(fù)測定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的M2-型丙酮酸激酶(PKM2)等多因子檢測試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測樣本,線性范圍即為稀釋后樣本中M2-型丙酮酸激酶(PKM2)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 94-101% | 79-90% | 88-96% | 85-102% |
EDTA plasma(n=5) | 94-102% | 82-97% | 91-99% | 78-99% |
heparin plasma(n=5) | 79-88% | 82-103% | 78-89% | 83-93% |
sodium citrate plasma(n=5) | 83-97% | 82-101% | 89-102% | 92-101% |
穩(wěn)定性
經(jīng)測定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測溶液B100μL,37°C振動(dòng)孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將M2-型丙酮酸激酶(PKM2)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的M2-型丙酮酸激酶(PKM2)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的M2-型丙酮酸激酶(PKM2)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的M2-型丙酮酸激酶(PKM2)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Homo sapiens (Human,人) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA588Hu01 | M2-型丙酮酸激酶(PKM2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA588Hu02 | M2-型丙酮酸激酶(PKM2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA588Hu03 | M2-型丙酮酸激酶(PKM2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APA588Hu02 | M2-型丙酮酸激酶(PKM2)活性蛋白 | Cell?culture;?Activity?Assays. |
PAA588Hu02 | M2-型丙酮酸激酶(PKM2)多克隆抗體 | WB; IHC; IF;FCM |
PAA588Hu03 | M2-型丙酮酸激酶(PKM2)多克隆抗體 | WB; IHC; ICC; IP. |
PAA588Hu01 | M2-型丙酮酸激酶(PKM2)多克隆抗體 | WB,IHC,ICC/IF; FCM |
FAA588Hu01 | 抗M2-型丙酮酸激酶(PKM2)多克隆抗體 | Flow cytometry. |
FAA588Hu03 | 抗M2-型丙酮酸激酶(PKM2)多克隆抗體 | Flow cytometry. |
MAA588Hu24 | M2-型丙酮酸激酶(PKM2)單克隆抗體 | WB; IHC; ICC; IP. |
MAA588Hu22 | M2-型丙酮酸激酶(PKM2)單克隆抗體 | WB; IHC; ICC; IP. |
MAA588Hu23 | M2-型丙酮酸激酶(PKM2)單克隆抗體 | WB; IHC; ICC; IP. |
MAA588Hu21 | M2-型丙酮酸激酶(PKM2)單克隆抗體 | WB; IHC; ICC; IP. |
SEA588Hu | M2-型丙酮酸激酶(PKM2)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA588Hu | M2-型丙酮酸激酶(PKM2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Cancer Research | Antigen Presentation by Dendritic Cells in Tumors Is Disrupted by Altered Metabolism that Involves Pyruvate Kinase M2 and Its Interaction with SOCS3 [AACR: 70189] |
Molecular BioSystems | Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer [Pubmed:25483567] |
Tumour Biol | M2 isoform of pyruvate kinase (PKM2) is upregulated in Kazakh’s ESCC and promotes proliferation and migration of ESCC cells [PubMed: 26404132] |
Oncotarget | Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis [Pubmed:29707118] |
Journal of?Neurotrauma | Acteoside improves muscle atrophy and motor function by inducing new myokine secretion in chronic spinal cord injury [Pubmed: 30318996] |
Cell Reports | Secreted Pyruvate Kinase M2 Promotes Lung Cancer Metastasis through Activating the Integrin Beta1/FAK Signaling Pathway [Pubmed: 32049010] |
Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC) [] | |
Cancer Cell International | Bufalin Induced Mitochondrial Dysfunction Promotes Apoptosis of Glioma Cells by Regulating Annexin A2 and DRP1 Proteins [] |
Cancer Cell Int | Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression [34376212] |
Life (Basel) | Putative Association between Low Baseline Gene Expression in the Peripheral Blood and Clinical Remission in Rheumatoid Arthritis Patients Treated with Tofacitinib [34947916] |